Researchers still pushing for better multiple sclerosis treatments

March 18, 2014 by Chris Thomas
Before 1996, there were no therapies to slow MS and the ones that followed required people to inject themselves; now there are oral medication options. Credit: Gerda

Two new oral treatments have become available for people with multiple sclerosis, helping to delay the progression of disability and reduce the frequency of relapse.

Diethyl fumarate, known as Tecfidera (and BG-12 in clinical trials), and teriflunomide, known as Aubagio, recently joined fingolimod (Gilenya) as oral treatments on the Pharmaceutical Benefits Scheme.

WA was involved in some clinical trials for the treatments and a patient familiarisation program and continues to monitor people on the medications through best clinical practice.

St John of God Subiaco Hospital clinical professor and consultant neurologist Allan Kermode manages a research team investigating causes of MS and says the development and testing of oral treatments has been an expensive, slow and painstaking process.

Before 1996, there were no therapies to slow MS and the ones that followed required people to inject themselves.

"Fingolimod was originally considered as a medication for organ transplants but it was found not to be very useful in that context," Professor Kermode says.

"Teriflunomide is a derivative of a drug commonly used for arthritis while dimethyl fumarate was a chance discovery because fumarate in the compound form had been used to treat psoriasis.

"The holy grail of these treatments is to reduce clinical progression of disability and the second benefit is a reduction in the relapse rate.

"These drugs all reduce the frequency and severity of attack for patients with MS—in the case of dimethyl fumarate, have suggested an 85 per cent reduction in the number of new inflammatory lesions.

"We would like to think that reduction in inflammation also facilitates recovery from attack."

Prof Kermode says the therapies are believed to have a beneficial effect in MS via the immune system but other mechanisms of action are also possible.

"You might say how can we select a drug when we don't really have any idea of how it works? But it's not that surprising when you consider we don't have any idea what causes MS," he says.

"The end points of therapy are also somewhat imprecise. If you're using a cancer treatment, you count how many people die. If you're testing an anti-hypertensive you measure the blood pressure.

"We don't really have any good target markers for MS because there are a number of different factors involved and this is due in no small part to the heterogeneity and variability of MS itself."

Currently, Prof Kermode is collecting blood from patients in an effort to pinpoint biomarkers, looking at RNA expression, and working as part of an Australian collaborative study to isolate pharmacotherapeutic biomarkers.

The two new treatments, diethyl fumarate known as Tecfidera, and teriflunomide known as Aubagio, were added to the Pharmaceutical Benefits Scheme in December 2013.

Explore further: New oral drug found to reduce relapses in multiple sclerosis patients

Related Stories

New oral drug found to reduce relapses in multiple sclerosis patients

October 6, 2011
A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

Unraveling complex genetic interplay for MS risks

July 15, 2013
A WA-cohort of patients has been used to study the risk modifying role of specific genes suspected to contribute to one's predisposition to multiple sclerosis (MS).

Ingredient in new MS drug linked to serious brain disease

April 24, 2013
(HealthDay)—The active ingredient in a drug that's expected to become a popular treatment for multiple sclerosis has been linked to four European cases of a rare but sometimes fatal brain disease called progressive multifocal ...

Patients curious about medical marijuana treatments

January 16, 2014
Ever since medical marijuana became legal in Illinois on Jan. 1, Loyola University Medical Center neurologist and multiple sclerosis specialist Dr. Matthew McCoyd has been inundated with questions from his patients.

New knowledge about treating multiple sclerosis

February 3, 2014
(Medical Xpress)—A study carried out at Victoria, and recently published online in the international scientific journal PLOS ONE, holds promise for patients suffering from secondary progressive MS, an advanced form of the ...

Cannabis constituent has no effect on MS progression, study shows

July 23, 2013
The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that ...

Recommended for you

Researchers find monkey brain structure that decides if viewed objects are new or unidentified

August 18, 2017
A team of researchers working at the University of Tokyo School of Medicine has found what they believe is the part of the monkey brain that decides if something that is being viewed is recognizable. In their paper published ...

Artificial neural networks decode brain activity during performed and imagined movements

August 18, 2017
Artificial intelligence has far outpaced human intelligence in certain tasks. Several groups from the Freiburg excellence cluster BrainLinks-BrainTools led by neuroscientist private lecturer Dr. Tonio Ball are showing how ...

How whip-like cell appendages promote bodily fluid flow

August 18, 2017
Researchers at Nagoya University have identified a molecule that enables cell appendages called cilia to beat in a coordinated way to drive the flow of fluid around the brain; this prevents the accumulation of this fluid, ...

Study of nervous system cells can help to understand degenerative diseases

August 18, 2017
The results of a new study show that many of the genes expressed by microglia differ between humans and mice, which are frequently used as animal models in research on Alzheimer's disease and other neurodegenerative disorders.

Researchers make surprising discovery about how neurons talk to each other

August 17, 2017
Researchers at the University of Pittsburgh have uncovered the mechanism by which neurons keep up with the demands of repeatedly sending signals to other neurons. The new findings, made in fruit flies and mice, challenge ...

Neurons involved in learning, memory preservation less stable, more flexible than once thought

August 17, 2017
The human brain has a region of cells responsible for linking sensory cues to actions and behaviors and cataloging the link as a memory. Cells that form these links have been deemed highly stable and fixed.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.